Fate Therapeutics (FATE) Stock Overview
A clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
FATE Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Fate Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.21 |
| 52 Week High | US$3.50 |
| 52 Week Low | US$0.66 |
| Beta | 2.35 |
| 1 Month Change | 21.00% |
| 3 Month Change | 8.04% |
| 1 Year Change | -62.42% |
| 3 Year Change | -94.36% |
| 5 Year Change | -97.48% |
| Change since IPO | -81.72% |
Recent News & Updates
Fate Therapeutics: Recent Update Met With Selling, But Positives Exist
Aug 29Here's Why We're Watching Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Aug 08
We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Apr 22Recent updates
Fate Therapeutics: Recent Update Met With Selling, But Positives Exist
Aug 29Here's Why We're Watching Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Aug 08We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Apr 22Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
Feb 05We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Jan 06Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
Nov 20Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts
Aug 21Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Aug 11Fate Therapeutics: Looking For A Potential Turnaround In 2024
Apr 29Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 23Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%
Feb 16Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks
Jan 26Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry
Dec 19Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?
Sep 08Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price
Jun 07Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%
May 08Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Apr 17We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
Jan 10Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Sep 22Fate Therapeutics: Yes For Speculators, No For Defensive Investors
Aug 30Needham initiates Fate coverage Therapeutics on potential of stem cell therapies
Jul 28Fate Therapeutics names Brian Powl as chief commercial officer
Jun 30Fate: Possible Speedy FDA Approval Process With RMAT Designation
Jun 03We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
Jun 02Shareholder Returns
| FATE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 21.0% | 5.2% | 1.2% |
| 1Y | -62.4% | -0.3% | 17.9% |
Return vs Industry: FATE underperformed the US Biotechs industry which returned 0.1% over the past year.
Return vs Market: FATE underperformed the US Market which returned 18.7% over the past year.
Price Volatility
| FATE volatility | |
|---|---|
| FATE Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FATE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: FATE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 181 | Bob Valamehr | www.fatetherapeutics.com |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors
Fate Therapeutics, Inc. Fundamentals Summary
| FATE fundamental statistics | |
|---|---|
| Market cap | US$139.55m |
| Earnings (TTM) | -US$171.52m |
| Revenue (TTM) | US$8.47m |
Is FATE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FATE income statement (TTM) | |
|---|---|
| Revenue | US$8.47m |
| Cost of Revenue | US$115.28m |
| Gross Profit | -US$106.81m |
| Other Expenses | US$64.72m |
| Earnings | -US$171.52m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.49 |
| Gross Margin | -1,260.99% |
| Net Profit Margin | -2,025.05% |
| Debt/Equity Ratio | 0% |
How did FATE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 18:28 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fate Therapeutics, Inc. is covered by 27 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Peter Lawson | Barclays |
| James Birchenough | BMO Capital Markets U.S. (Historical) |